Research Analysts Offer Predictions for PVLA FY2024 Earnings

Palvella Therapeutics (NASDAQ:PVLA) – Equities researchers at HC Wainwright issued their FY2024 earnings estimates for shares of Palvella Therapeutics in a report issued on Thursday, December 26th. HC Wainwright analyst A. Fein forecasts that the company will earn ($4.37) per share for the year. HC Wainwright has a “Buy” rating and a $38.00 price objective on the stock.

Separately, Cantor Fitzgerald initiated coverage on shares of Palvella Therapeutics in a research report on Wednesday, December 18th. They set an “overweight” rating for the company.

Palvella Therapeutics Stock Performance

PVLA opened at $12.00 on Monday. Palvella Therapeutics has a 52 week low of $6.20 and a 52 week high of $22.32. The company has a market cap of $15.84 million, a price-to-earnings ratio of -0.99 and a beta of 0.61.

Insider Buying and Selling at Palvella Therapeutics

In other news, Director George M. Jenkins bought 4,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 18th. The stock was acquired at an average price of $12.93 per share, with a total value of $51,720.00. Following the completion of the purchase, the director now directly owns 180,671 shares of the company’s stock, valued at $2,336,076.03. This represents a 2.26 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. 6.39% of the stock is currently owned by insiders.